Vitamin D insufficiency in diabetic retinopathy

Endocrine Practice

Volumn 18, Issue 2, 2012, Pages 185-193

  Payne, John F ^a   Ray, Robin ^a   Watson, David G ^b   Delille, Cecile ^b   Rimler, Eva ^b   Cleveland, Julia ^a   Lynn, Michael J ^a   Tangpricha, Vin ^b,c   Srivastava, Sunil K ^a  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c ATLANTA VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CREATININE; HEMOGLOBIN A1C; MULTIVITAMIN; VITAMIN D;

ADULT; AGED; ARTICLE; BODY MASS; CREATININE BLOOD LEVEL; CROSS-SECTIONAL STUDY; DIABETES MELLITUS; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; OPHTHALMOSCOPY; TREATMENT DURATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION;

EID: 84859869159     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP11147.OR     Document Type: Article

References (29)

1. Centers for Disease Control and Prevention. 2007 national diabetes fact sheet: General information and national estimates on diabetes in the United States, 2007. http://www.cdc.gov/diabetes/pubs/factsheet07.htm. Accessed for verification October 6, 2011.
2. Narayan KM, Boyle JP, Geiss LS, Saaddine JB, Thompson TJ. Impact of recent increase in incidence on future diabetes burden: U.S., 2005-2050. Diabetes Care. 2006;29:2114-2116.
3. Klein R, Klein BE, Moss SE. Relationship of glycemic control to diabetic microvascular complications in diabetes mellitus. Ann Intern Med. 1996;124(1, pt 2):90-96.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in Lancet. 1999;354:602]. Lancet. 1998;352:837-853.
5. Chew EY, Ambrosius WT, Davis MD, et al (ACCORD Study Group; ACCORD Eye Study Group). Effects of medical therapies on retinopathy progression in type 2 diabetes [published correction appears in N Engl J Med. 2011; 364:190]. N Engl J Med. 2010;363:233-244.
6. Holick MF. Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis [published correction appears in Am J Clin Nutr. 2004;79:890]. Am J Clin Nutr. 2004;79:362-371.
7. Baz-Hecht M, Goldfine AB. The impact of vitamin D deficiency on diabetes and cardiovascular risk. Curr Opin Endocrinol Diabetes Obes. 2010;17:113-119.
8. Judd SE, Tangpricha V. Vitamin D deficiency and risk for cardiovascular disease. Am J Med Sci. 2009;338:40-44.
9. Simpson S Jr, Taylor B, Blizzard L, et al. Higher 25-hydroxyvitamin D is associated with lower relapse risk in multiple sclerosis. Ann Neurol. 2010;68:193-203.
10. Evatt ML, Delong MR, Khazai N, Rosen A, Triche S, Tangpricha V. Prevalence of vitamin D insufficiency in patients with Parkinson disease and Alzheimer disease. Arch Neurol. 2008;65:1348-1352.
11. Palomer X, González-Clemente JM, Blanco-Vaca F, Mauricio D. Role of vitamin D in the pathogenesis of type 2 diabetes mellitus. Diabetes Obes Metab. 2008;10:185-197.
12. Albert DM, Scheef EA, Wang S, et al. Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci. 2007;48:2327-2334.
13. Bischoff-Ferrari HA, Giovanucci E, Willett WC, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes [published corrections appear in Am J Clin Nutr. 2006;84:1253 and Am J Clin Nutr. 2007;86:809]. Am J Clin Nutr. 2006;84:18-28.
14. Pepper KJ, Judd SE, Nanes MS, Tangpricha V. Evaluation of vitamin D repletion regimens to correct vitamin D status in adults. Endocr Pract. 2009;15:95-103.
15. Jablonski KL, Chonchol M, Pierce GL, Walker AE, Seals DR. 25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension. 2011;57:63-69.
16. Ben-Shoshan M, Amir S, Dang DT, Dang LH, Weisman Y, Mabjeesh NJ. 1alpha,25-Dihydroxyvitamin D3 (calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells. Mol Cancer Ther. 2007;6:1433-1439.
17. Wang J, Xu X, Elliott MH, Zhu M, Le YZ. Müller cell-derived VEGF is essential for diabetes-induced retinal inflammation and vascular leakage. Diabetes. 2010;59: 2297-2305.
18. Wakabayashi Y, Usui Y, Okunuki Y, et al. Correlation of vascular endothelial growth factor with chemokines in the vitreous in diabetic retinopathy. Retina. 2010;30:339-344.
19. Wang X, Wang G, Wang Y. Intravitreous vascular endothelial growth factor and hypoxia-inducible factor 1a in patients with proliferative diabetic retinopathy. Am J Ophthalmol. 2009;148:883-889.
20. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 [published correction appears in BMJ. 1999;318:29]. BMJ. 1998;317: 703-713.
21. Gedik O, Akalin S. Effects of vitamin D deficiency and repletion on insulin and glucagon secretion in man. Diabetologia. 1986;29:142-145.
22. Chiu KC, Chu A, Go VL, Saad MF. Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr. 2004;79:820-825.
23. Pittas AG, Harris SS, Stark PC, Dawson-Hughes B. The effects of calcium and vitamin D supplementation on blood glucose and markers of inflammation in nondiabetic adults. Diabetes Care. 2007;30:980-986.
24. Kristal-Boneh E, Froom P, Harari G, Ribak J. Association of calcitriol and blood pressure in normotensive men. Hypertension. 1997;30:1289-1294.
25. Judd SE, Nanes MS, Ziegler TR, Wilson PW, Tangpricha V. Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: Results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr. 2008;87:136-141.
26. Forman JP, Giovannucci E, Homes MD, et al. Plasma 25-hydroxyvitamin D levels and risk of incident hypertension. Hypertension. 2007;49:1063-1069.
27. Aksoy H, Akçay F, Kurtul N, Baykal O, Avci B. Serum 1,25 dihydroxy vitamin D (1,25(OH)2D3), 25 hydroxy vitamin D (25(OH)D) and parathormone levels in diabetic retinopathy. Clin Biochem. 2000;33:47-51.
28. Vashi PG, Lammersfeld CA, Braun DP, Gupta D. Serum 25-hydroxyvitamin D is inversely associated with body mass index in cancer. Nutr J. 2011;10:51.
29. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ. Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol [published correction appears in Am J Clin Nutr. 2003;78:1047]. Am J Clin Nutr. 2003;77:204-210.